NeoGenomics (NEO) CAO converts RSUs to stock and withholds shares for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeoGenomics Chief Accounting Officer Greg D. Aunan reported equity compensation activity. On February 21, 2026, he exercised 6,323 restricted stock units, converting them into the same number of shares of common stock at $0.00 per share, reflecting vesting of prior RSU grants. On the same date, 1,875 common shares were withheld and disposed of to cover tax obligations related to the RSU release, rather than an open-market sale. Following these transactions, he directly held 22,027 shares of common stock and maintained multiple outstanding stock option and RSU awards that vest over future anniversaries of their respective grant dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
6,323 shares exercised/converted
Mixed
7 txns
Insider
Aunan Greg D
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 6,323 | $0.00 | -- |
| Exercise | Common Stock | 6,323 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,875 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 12,648 shares (Direct);
Common Stock — 23,902 shares (Direct);
Stock Option (Right to Buy) — 28,662 shares (Direct)
Footnotes (1)
- Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration. On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date.
FAQ
What insider transaction did NeoGenomics (NEO) disclose for Greg D. Aunan?
NeoGenomics reported equity compensation activity for Chief Accounting Officer Greg D. Aunan. He converted 6,323 restricted stock units into common shares and had 1,875 shares withheld to satisfy tax obligations, reflecting vesting of prior awards rather than an open-market share purchase or sale.
What happened to the 6,323 restricted stock units in the NeoGenomics (NEO) Form 4?
The 6,323 restricted stock units were converted into 6,323 NeoGenomics common shares at $0.00 per share upon vesting. Each restricted stock unit is economically equivalent to one share of common stock and becomes actual stock once vesting conditions under the grant are met.
What longer-term equity awards does the NeoGenomics (NEO) CAO hold?
Footnotes show multiple stock option and RSU grants, including options granted in May 2023 and May 2024 and RSUs granted in May 2024 and February 2025. These awards generally vest ratably over three or four years from their grant dates, supporting ongoing equity alignment.